Stock NGLFINE NGL FINE-CHEM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials NGL Fine-Chem Limited

Equities

NGLFINE

INE887E01022

Pharmaceuticals

Delayed Bombay S.E.
Other stock markets
 06:00:48 2024-04-30 am EDT 		5-day change 1st Jan Change
2,548 INR +0.55% Intraday chart for NGL Fine-Chem Limited -1.42% +14.17%
Apr. 19 NGL Fine-Chem Limited Approves the Appointment of Dhananjay Mungale as Independent Director CI
Mar. 29 Crisil Keeps NGL Fine-Chem Rating at BBB+; Outlook Stable MT

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 2,537 2,902 1,565 9,471 12,095 7,394
Enterprise Value (EV) 1 2,701 3,055 1,709 9,297 12,100 7,194
P/E ratio 20.1 x 14.4 x 18.8 x 16.7 x 24.2 x 36.1 x
Yield - 0.37% 0.69% 0.11% 0.09% 0.15%
Capitalization / Revenue 2.23 x 1.89 x 1.03 x 3.67 x 3.81 x 2.66 x
EV / Revenue 2.38 x 1.99 x 1.13 x 3.6 x 3.81 x 2.59 x
EV / EBITDA 12.7 x 8.62 x 7.94 x 11 x 17.9 x 21.1 x
EV / FCF -69.2 x -25.3 x 35.1 x 41.3 x -21.3 x 44.7 x
FCF Yield -1.45% -3.96% 2.85% 2.42% -4.69% 2.24%
Price to Book 3.52 x 3.15 x 1.58 x 6.13 x 5.95 x 3.32 x
Nbr of stocks (in thousands) 6,178 6,178 6,178 6,178 6,178 6,178
Reference price 2 410.6 469.8 253.4 1,533 1,958 1,197
Announcement Date 5/18/18 7/27/19 7/20/20 7/24/21 6/6/22 8/1/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net sales 1 1,137 1,532 1,517 2,580 3,175 2,781
EBITDA 1 212.6 354.5 215.3 841.8 676.8 341.6
EBIT 1 167.9 292.4 135.2 759.6 574.8 230.3
Operating Margin 14.77% 19.09% 8.91% 29.45% 18.1% 8.28%
Earnings before Tax (EBT) 1 178 275.7 120.7 775.9 666 273.6
Net income 1 125.9 201.3 83.35 567.2 499 205
Net margin 11.08% 13.14% 5.5% 21.99% 15.72% 7.37%
EPS 2 20.38 32.58 13.49 91.81 80.77 33.18
Free Cash Flow 1 -39.06 -121 48.7 225.2 -566.9 161
FCF margin -3.44% -7.9% 3.21% 8.73% -17.85% 5.79%
FCF Conversion (EBITDA) - - 22.62% 26.75% - 47.12%
FCF Conversion (Net income) - - 58.43% 39.7% - 78.54%
Dividend per Share - 1.750 1.750 1.750 1.750 1.750
Announcement Date 5/18/18 7/27/19 7/20/20 7/24/21 6/6/22 8/1/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 165 153 144 - 4.52 -
Net Cash position 1 - - - 174 - 200
Leverage (Debt/EBITDA) 0.7748 x 0.4325 x 0.6698 x - 0.006684 x -
Free Cash Flow 1 -39.1 -121 48.7 225 -567 161
ROE (net income / shareholders' equity) 19.2% 24.5% 8.72% 44.8% 27.9% 9.63%
ROA (Net income/ Total Assets) 9.07% 13.5% 5.71% 26.3% 14.8% 5.1%
Assets 1 1,389 1,495 1,459 2,159 3,364 4,016
Book Value Per Share 2 117.0 149.0 160.0 250.0 329.0 360.0
Cash Flow per Share 2 2.410 1.280 0.6500 3.400 1.040 12.70
Capex 1 239 145 149 172 564 314
Capex / Sales 20.99% 9.47% 9.83% 6.67% 17.76% 11.29%
Announcement Date 5/18/18 7/27/19 7/20/20 7/24/21 6/6/22 8/1/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Veterinary Drugs

1st Jan change Capi.
NGL FINE-CHEM LIMITED Stock NGL Fine-Chem Limited
+14.17% 189M
ZOETIS INC. Stock Zoetis Inc.
-19.32% 72.76B
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-11.68% 6.49B
VIRBAC Stock Virbac
-3.48% 3.11B
VIMIAN GROUP AB Stock Vimian Group AB
+2.36% 1.44B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-15.13% 1.37B
VETOQUINOL SA Stock Vetoquinol SA
-7.91% 1.19B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-25.63% 1.24B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-10.84% 1.17B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-.--% 1.05B
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. NGLFINE Stock
  4. Financials NGL Fine-Chem Limited